Enlivex Therapeutics Analyst Ratings
Enlivex Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a reiterated with a price target of $0.00 to $15.00. The current price Enlivex Therapeutics (ENLV) is trading at is $3.90, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | 284.62% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 05/02/2022 | 284.62% | HC Wainwright & Co. | $33 → $15 | Maintains | Buy |
| 01/09/2020 | 412.82% | HC Wainwright & Co. | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 02/24/2023 | 284.62% | HC Wainwright & Co. | → 15 美元 | 重申 | → 购买 |
| 05/02/2022 | 284.62% | HC Wainwright & Co. | 33 美元 → 15 美元 | 维护 | 买 |
| 01/09/2020 | 412.82% | HC Wainwright & Co. | → 20 美元 | 开启覆盖范围 | → 购买 |
What is the target price for Enlivex Therapeutics (ENLV)?
Enlivex Therapeutics（ENLV）的目标价格是多少？
The latest price target for Enlivex Therapeutics (NASDAQ: ENLV) was reported by HC Wainwright & Co. on February 24, 2023. The analyst firm set a price target for $15.00 expecting ENLV to rise to within 12 months (a possible 284.62% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年2月24日公布了Enlivex Therapeutics（纳斯达克股票代码：ENLV）的最新目标股价。这家分析公司将目标价设定为15.00美元，预计ENLV将在12个月内升至284.62％（可能上涨284.62％）。去年，有两家分析公司公布了评级。
What is the most recent analyst rating for Enlivex Therapeutics (ENLV)?
Enlivex Therapeutics（ENLV）的最新分析师评级是多少？
The latest analyst rating for Enlivex Therapeutics (NASDAQ: ENLV) was provided by HC Wainwright & Co., and Enlivex Therapeutics reiterated their buy rating.
Enlivex Therapeutics（纳斯达克股票代码：ENLV）的最新分析师评级由HC Wainwright & Co. 提供，Enlivex Therapeutics重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Enlivex Therapeutics (ENLV)?
Enlivex Therapeutics（ENLV）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enlivex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enlivex Therapeutics was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与Enlivex Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。Enlivex Therapeutics的最新评级是在2023年2月24日公布的，因此你应该预计下一个评级将在2024年2月24日左右公布。
Is the Analyst Rating Enlivex Therapeutics (ENLV) correct?
分析师对Enlivex Therapeutics（ENLV）的评级是否正确？
While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a reiterated with a price target of $0.00 to $15.00. The current price Enlivex Therapeutics (ENLV) is trading at is $3.90, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Enlivex Therapeutics（ENLV）评级得到了重申，目标价为0.00美元至15.00美元。Enlivex Therapeutics（ENLV）目前的交易价格为3.90美元，在分析师的预测区间内。
译文内容由第三方软件翻译。
